Prospective Multi-omics Observational Study of Gynecological Rare Pathological Tumors
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Rare Gynecological Tumors
- Sponsor
- RenJi Hospital
- Enrollment
- 600
- Primary Endpoint
- Multi-omics feature map
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
The goal of this observational study is to draw the characteristic maps of genomics, transcriptome, proteomics, metabolomics, etc. in 600 patients with gynecological rare pathological types of malignant tumors. Then it is planned to explore the molecular mechanism and find some new targets for diagnosis and treatment, and design and establish the database system of the above rare tumors.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Pathological diagnosis: clear cell carcinoma (ovary, uterus), nerve small-cell carcinoma (ovary, uterus), carcinosarcoma or sarcoma (ovary, uterus), cervical gastric adenocarcinoma, ovarian germ cell tumor, ovarian sex cord stromal tumor, trophoblastic tumor, perivascular epithelioid cell tumor (PECOMA) and other rare gynecological tumors; 2)Received pathological results from tumor surgery; 3)The patient voluntarily participated in this research project with good compliance and was able to complete the enrollment according to the experimental requirements; 4)Sign the informed consent form and consent to the collection and use of their data, and consent to genomics, transcriptome and other tests.
Exclusion Criteria
- •Patients with malignant tumors in other parts of the body; 2)Suffering from uncontrollable neurological diseases, psychiatric diseases, or psychiatric disorders; 3)Poor compliance and inability to cooperate and describe treatment responders.
Outcomes
Primary Outcomes
Multi-omics feature map
Time Frame: August 2023 to May 2028
Draw the characteristic maps of imaging omics, genomics, transcriptome, proteomics, pathological omics, metabolomics, etc. of patients with gynecological rare pathological types of malignant tumors, and explore the molecular mechanism thus finding some new targets for diagnosis and treatment.
Database system
Time Frame: August 2023 to May 2028
Design and establish the database system of the above gynecological rare pathological types of tumors.
Secondary Outcomes
- Correlation analysis(August 2023 to May 2028)